top of page


                                 Our main area of expertise are Oral Dissolvable Strips (ODS) / Oral Thin Film (OTF). And ODS is a thin, stamp-sized, flavored carrier matrix that combines the best attributes of tablets, liquids, and more. ODS adhere to the tongue, the cheek, or the roof of the mouth, where they dissolve and release the active ingredient. Their dissolution time and place are adjustable, they are lighter than tablets and can even be administered to unconscious patients. ​Plus, we flavor-mask the taste of bitter-tasting ingredients. ODS enable custom-dosing and improve patient adherence where it is a challenge such as in pediatrics or geriatrics. ​Our patent-protected ODS have significantly higher API loading than industry competitors, and we have pushed the limits on customized dissolution rates from seconds to up to 8 hours.​​​ Oak Therapeutics holds multiple patents and trade secrets.


                           We are a formulation company with core capabilities in Oral Dissolvable Strips (ODS) / Oral Thin Film (OTF). We currently have several ODS/OTF products in various stages of development including the following:​

  • Amoxicillin (antibiotic)​

  • Isoniazid (tuberculosis)​

  • Isoniazid-Rifapentine (tuberculosis)​

  • Maropitant (motion-sickness / vomiting in pets)​

  • Xerostrip (dry mouth)​

  • Abacavir-Dolutegravir-Lamivudine (ALD) combination treatment (HIV)​

We have the capability to work with a wide range of APIs and reformulate them for Oral Dissolvable Strips (ODS/OTF) with a drug loading up to 400mg per ODS and time release from seconds to multiple hours.​



                                                    Over the last several years, we have perfected our technology in cooperation with outside partners from research and industry, including the Children's Hospital of Los Angeles (CHLA), the University of Kansas Medical Center (KUMC), the University of Southern California (USC) Department of Pharmacology. Some of our most impactful research has been funded by the National Institutes of Health (NIH) through federally funded projects and contracts. Here are a few examples of our recently published research:


  • Wexler, C., Maloba, M., Sliefert, M., Maliski, E., Nicolay, Z. et al. Assessing user preferences for design characteristics of oral dissolvable strips for pediatric HIV medication: a qualitative study.BMC Health Serv Res 23, 1103 (2023).

  • Sliefert, M., Maloba, M., Wexler, C., Were, F., Mbithi, Y., Mugendi, G., Maliski, E., Nicolay, Z.... & Finocchario-Kessler, S. (2024). Challenges with pediatric antiretroviral therapy administration: Qualitative perspectives from caregivers and HIV providers in Kenya. Plos one, 19(1), e0296713.


Interested in hearing more? Contact us!

  • LinkedIn
  • Twitter

31416 Agoura Rd. Ste. 105

Westlake Village, CA 91361


2029 Becker

Lawrence, KS 66047

ph +1 (913) 346-0990

bottom of page